ClinicalTrials.gg

Program

tirbanibulin

Also written as “KX2-391”, “Tirbanibulin ointment 1%” and “KX01 ointment 1%”.

Its studies are mostly in Keratosis, Actinic · Warts · Psoriasis · Prostatic Neoplasms · Dermatitis, Phototoxic, led by 5 companies.

Furthest: phase 4, since May 19, 202212 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Almirall41 open or runningphase 4since May 19, 2022Mar 1, 2022Jul 2027phase 4 · NCT05387525
Athenex30 open or runningphase 2since Feb 22, 2010Jan 15, 2008none ahead
PharmaEssentia30 open or runningphase 3since Jan 28, 2022Dec 30, 2021none ahead
Hanmi Pharmaceutical10 open or runningphase 2since Jan 2, 2013Jan 2, 2013none ahead
The Skin Center Dermatology Group11 open or runningphase 4since Jan 19, 2025Jan 19, 2025none ahead

Also a collaborator on its studies: pharmaessentia-japan-k-k.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2008First study: phase 1 study in LymphomaNew to AthenexAthenex · NCT00658970 · 50 enrolled · United States
  2. Feb 22, 2010Phase 2 study in Bone-Metastatic, Castration-Resistant Prostate CancerAthenex · NCT01074138 · 31 enrolled · United States
  3. Jul 18, 2011Phase 1 study in Leukemia, Myeloid, AcuteAthenex · NCT01397799 · 24 enrolled · United States
  4. Jan 2, 2013Hanmi Pharmaceutical's first study: phase 2 study in Stomach NeoplasmsNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01764087 · 60 enrolled · Korea, Republic of
  5. Dec 30, 2021PharmaEssentia's first study: phase 1 study in Dermatitis, PhototoxicNew to PharmaEssentiaPharmaEssentia · NCT05245578 · 20 enrolled · Japan
  6. Jan 28, 2022Phase 3 study in Keratosis, ActinicPharmaEssentia · NCT05231044 · 108 enrolled · Japan
  7. Mar 1, 2022Almirall's first study: phase 3 study in Keratosis, ActinicNew to AlmirallAlmirall · NCT05279131 · 105 enrolled · United States
  8. May 19, 2022Phase 4 study in Keratosis, ActinicAlmirall · NCT05387525 · 447 enrolled · France, Germany, Italy and more
  9. Aug 25, 2022Phase 1 study in PsoriasisPharmaEssentia · NCT05522816 · 28 enrolled
  10. Feb 14, 2023Phase 4 study in Keratosis, ActinicAlmirall · NCT05741294 · 334 enrolled · Italy, Spain
  11. Nov 13, 2023Phase 3 study in Keratosis, ActinicAlmirall · NCT06135415 · 280 enrolled · Germany, Italy, Netherlands and more
  12. Jan 19, 2025The Skin Center Dermatology Group's first study: phase 4 study in Warts HandNew to The Skin Center Dermatology GroupThe Skin Center Dermatology Group · NCT06791525 · 10 planned · United States

Ahead

  1. Nov 1, 2026Primary completion: phase 4 study in Warts HandThe Skin Center Dermatology Group · NCT06791525
  2. Jul 2027Primary completion: phase 4 study in Keratosis, ActinicAlmirall · NCT05387525

TargetBeta

SRC →read by rule
“Tyrosine-protein kinase SRC inhibitor”ChEMBL 37, by rule

Other programs on SRC

ProgramCompanyFurthest phaseStudies
repotrectinibruleBristol-Myers Squibbphase 39
SRC/YES1 Kinase Inhibitor NXP900rulenuvectis-pharma-incphase 13

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06791525Warts Hand · United States4RecruitingThe Skin Center Dermatology GroupNov 1, 202610
NCT06135415Keratosis, Actinic · Germany, Italy, Netherlands and more3CompletedAlmirallApr 30, 2025280
NCT05741294Keratosis, Actinic · Italy, Spain4CompletedAlmirallJan 19, 2024334
NCT05522816Psoriasis1CompletedPharmaEssentiaMar 10, 202128
NCT05387525Keratosis, Actinic · France, Germany, Italy and more4Active, not recruitingAlmirallJul 2027447
NCT05279131Keratosis, Actinic · United States3CompletedAlmirallDec 28, 2022105
NCT05231044Keratosis, Actinic · Japan3CompletedPharmaEssentiaNov 20, 2023108
NCT05245578Dermatitis, Phototoxic · Japan1CompletedPharmaEssentiaNov 22, 202120
NCT01764087Stomach Neoplasms · Korea, Republic of2UNKNOWNHanmi PharmaceuticalDec 201560
NCT01397799Leukemia, Myeloid, Acute · United States1CompletedAthenexJul 201424
NCT01074138Bone-Metastatic, Castration-Resistant Prostate Cancer · United States2CompletedAthenexJun 201231
NCT00658970Lymphoma · United States1CompletedAthenexMar 201050

How it is read

Names in the registry

  • “KX2-391”, 3 entries
  • “Tirbanibulin ointment 1%”, 2 entries
  • “KX01 ointment 1%”, 2 entries
  • “Tirbanibulin”, 1 entry
  • “KX01 0.01% (0.1 mg/g)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.